A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis

American Journal of Tropical Medicine and Hygiene

Volumn 83, Issue 1, 2010, Pages 97-101

  López Jaramillo, Patricio ^a   Rincón, Melvin Y ^a   García, Ronald G ^a   Silva, Sandra Y ^a   Smith, Erin ^b   Kampeerapappun, Piyaporn ^b   García, Carlos ^c   Smith, Daniel J ^b   López, Marcos ^d   Vélez, Iván D ^e  

^a FUNDACIÓN CARDIOVASCULAR DE COLOMBIA   (Colombia)

^b UNIVERSITY OF AKRON   (United States)

^c Laboratorio Salud Pública de Santander   (Colombia)

^d FREE RADICAL RESEARCH CENTER   (United States)

^e UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; NANOFIBER; NITRIC OXIDE; PLACEBO;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CHILD; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG RELEASE; ELECTROSPINNING; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LEISHMANIA PANAMENSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; PAIN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SKIN LEISHMANIASIS; TRANSDERMAL PATCH; TREATMENT RESPONSE; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ASTRINGENTS; ATHEROSCLEROSIS; COLOMBIA; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; LEISHMANIASIS, CUTANEOUS; NITRIC OXIDE; TREATMENT OUTCOME;

LEISHMANIA PANAMENSIS;

EID: 77954599023     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2010.09-0287     Document Type: Article

References (34)

1. Singh S, Sivakumar R, 2003. Recent advances in the diagnosis of leishmaniasis. J Postgrad Med 49: 55-60.
2. Desjeux P, 1996. Leishmaniasis. Public health aspects and control. Clin Dermatol 14: 417-423.
3. Herwaldt BL, 1999. Leishmaniasis. Lancet 354: 1191-1199.
4. Panamerican Health Organization, 2008. Leishmaniasis: 2007 update. Available at: http://www.paho.org/English/AD/DPC/CD/leish-2007.htm. Accessed April 29, 2009.
5. Bern C, Maguire JH, Alvar J, 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.
6. Roberts LJ, Handman E, Foote SJ, 2000. Science, medicine, and the future: leishmaniasis. BMJ 321: 801-804.
7. Hepburn NC, 2003. Cutaneous leishmaniasis: an overview. J Postgrad Med 49: 50-54.
8. Silveira FT, Lainson R, Corbett CE, 2004. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 99: 239-251. (Pubitemid 38822274)
9. Hepburn NC, Tidman MJ, Hunter JA, 1993. Cutaneous leishmaniasis in British troops from Belize. Br J Dermatol 128: 63-68.
10. Hendrickx EP, Agudelo SP, Munoz DL, Puerta JA, Velez Bernal ID, 1998. Lack of efficacy of mefloquine in the treatment of New World cutaneous leishmaniasis in Colombia. Am J Trop Med Hyg 59: 889-892.
11. Soto J, Fuya P, Herrera R, Berman J, 1998. Topical paromomycin/ methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26: 56-58. (Pubitemid 28068155)
12. Berman JD, 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24: 684-703.
13. Miller MA, McGowan SE, Gantt KR, Champion M, Novick SL, Andersen KA, Bacchi CJ, Yarlett N, Britigan BE, Wilson ME, 2000. Inducible resistance to oxidant stress in the protozoan Leishmania chagasi. J Biol Chem 275: 33883-33889.
14. Diaz NL, Fernandez M, Figueira E, Ramirez R, Monsalve IB, Tapia FJ, 2003. Nitric oxide and cellular immunity in experimental cutaneous leishmaniasis. Clin Exp Dermatol 28: 288-293. (Pubitemid 36713820)
15. Diefenbach A, Schindler H, Rollinghoff M, Yokoyama WM, Bogdan C, 1999. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 284: 951-955. (Pubitemid 29288431)
16. Gantt KR, Goldman TL, McCormick ML, Miller MA, Jeronimo SM, Nascimento ET, Britigan BE, Wilson ME, 2001. Oxidative responses of human and murine macrophages during phagocytosis of Leishmania chagasi. J Immunol 167: 893-901.
17. Kemp M, 1997. Regulator and effector functions of T-cell subsets in human Leishmania infections. APMIS 68 (Suppl): 1-33. (Pubitemid 27090692)
18. Liew FY, Millott S, Parkinson C, Palmer RM, Moncada S, 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol 144: 4794-4797. (Pubitemid 20224118)
19. Qadoumi M, Becker I, Donhauser N, Rollinghoff M, Bogdan C, 2002. Expression of inducible nitric oxide synthase in skin lesions of patients with American cutaneous leishmaniasis. Infect Immun 70: 4638-4642. (Pubitemid 34790977)
20. Davidson RN, Yardley V, Croft SL, Konecny P, Benjamin N, 2000. A topical nitric oxide-generating therapy for cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 94: 319-322. (Pubitemid 30406570)
21. Lopez-Jaramillo P, Ruano C, Rivera J, Teran E, Salazar-Irigoyen R, Esplugues JV, Moncada S, 1998. Treatment of cutaneous leishmaniasis with nitric-oxide donor. Lancet 351: 1176-1177.
22. Hansen L, Kataphinan W, Reneker D, Smith D, 2004. Production of superabsorbent electrospun nanofibers. Polym Mater Sci Eng 90: 508.
23. Lopez M, Lopez-Jaramillo P, Smith D, 2006. Topical Nitric Oxide Donor Devices. PCT/US2005/043051.
24. Smith D, 2005. Stabilization and Ionic Triggering of Nitric Oxide Release. PCT/US2004/023867.
25. Kenawy el-R, Bowlin GL, Mansfield K, Layman J, Simpson DG, Sanders EH, Wnek GE, 2002. Release of tetracycline hydrochloride from electrospun poly(ethylene-co-vinylacetate), poly (lactic acid), and a blend. J Control Release 81: 57-64.
26. Kenawy el-R, Layman JM, Watkins JR, Bowlin GL, Matthews JA, Simpson DG, Wnek GE, 2003. Electrospinning of poly(ethylene-co-vinyl alcohol) fibers. Biomaterials 24: 907-913.
27. Asilian A, Jalayer T, Whitworth JA, Ghasemi RL, Nilforooshzadeh M, Olliaro P, 1995. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 53: 648-651.
28. Robledo S, Puerta J, Munoz D, Guardo M, Velez I, 2006. Eficacia y tolerancia de la pentamidina en el tratamiento de la leishmaniasis cutánea producida por Leishmania (V.) panamensis en Colombia. Biomedica (Bogota) 26: 188-193.
29. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232-236.
30. Hibbs J Jr, Taintor R, Vavrin Z, 1987. Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235: 473-476. (Pubitemid 17009584)
31. MacMicking J, Xie QW, Nathan C, 1997. Nitric oxide and macrophage function. Annu Rev Immunol 15: 323-350. (Pubitemid 27169284)
32. De Groote M, Fang F, 1995. No inhibitions: antimicrobial properties of nitric oxide. Clin Infect Dis 21 (Suppl 2): S162.
33. Yim C-Y, Bastian N, Smith J, Hibbs J, Samlowski W, 1993. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res 53: 5507.
34. Stuehr D, Nathan C, 1989. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 169: 1543-1555. (Pubitemid 19126814)